HRTX vs HRGN: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

HRTX has stronger fundamentals based on our AI analysis.

HRTX
HERON THERAPEUTICS, INC. /DE/
STRONG SELL
87%
Confidence
VS
HRGN
Harvard Apparatus Regenerative Technology, Inc.
STRONG SELL
85%
Confidence

HRTX vs HRGN Fundamental Comparison

Metric HRTX HRGN
Revenue $154.9M $704,000.0
Net Income $-20.2M $-6.9M
Net Margin -13.0% -975.7%
ROE -140.9% -649.9%
ROA -7.9% -256.6%
Current Ratio 2.48x 1.19x
Debt/Equity 0.00x 0.00x
EPS $-0.12 $-0.44

Green = Better metric | Red = Weaker metric

View Full HRTX Analysis →
View Full HRGN Analysis →

You Might Also Compare

HRTX vs AAPL HRGN vs MSFT HRTX vs GOOGL HRGN vs AMZN

HRTX vs HRGN: Frequently Asked Questions

Is HRTX or HRGN a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), HRTX has stronger fundamentals. HRTX is rated STRONG SELL (87% confidence) while HRGN is rated STRONG SELL (85% confidence). This is not investment advice.

How does HRTX compare to HRGN fundamentally?

HERON THERAPEUTICS, INC. /DE/ has ROE of -140.9% vs Harvard Apparatus Regenerative Technology, Inc.'s -649.9%. Net margins are -13.0% vs -975.7% respectively.

Which stock pays higher dividends, HRTX or HRGN?

HRTX has a dividend yield of N/A or no dividend while HRGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in HRTX or HRGN for long term?

For long-term investing, consider that HRTX has STRONG SELL rating with 87% confidence, while HRGN has STRONG SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about HRTX vs HRGN?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For HRTX vs HRGN, the AI consensus favors HRTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.